Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.

Antimicrobial Agents and Chemotherapy
Maria M Traczewski, S D Brown

Abstract

Retapamulin, the first pleuromutilin antimicrobial agent approved for the topical treatment of skin infections in humans, was tested against 987 clinical isolates representing 30 species and/or resistance groups. MICs were determined along with disk diffusion zone diameters using a 2-microg disk. Population distribution and MIC versus disk zone diameter scattergrams were analyzed to determine microbiological MIC cutoff values and inhibition zone correlates. Minimum bactericidal concentrations were performed on a smaller subset of key species. The retapamulin MIC(90) against 234 Staphylococcus aureus isolates and 110 coagulase-negative staphylococci was 0.12 microg/ml. Retapamulin MIC(90)s ranged from 0.03 to 0.06 microg/ml against beta-hemolytic streptococci including 102 Streptococcus pyogenes, 103 Streptococcus agalactiae, 59 group C Streptococcus, and 71 group G Streptococcus isolates. The MIC(90) against 55 viridans group streptococci was 0.25 microg/ml. Retapamulin had very little activity against 151 gram-negative bacilli and most of the Enterococcus species tested. Based on the data from this study, for staphylococci, MICs of <or=0.5, 1, and >or=2 microg/ml with corresponding disk diffusion values of >or=20 mm, 17 to 19 ...Continue Reading

References

Sep 1, 1951·Proceedings of the National Academy of Sciences of the United States of America·F KavanaghW J Robbins
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Ronald N JonesJames E Ross
Oct 27, 2006·Antimicrobial Agents and Chemotherapy·Stephen RittenhouseDavid Payne
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Chen DavidovichAda Yonath
Jul 17, 2007·Clinical Microbiology Reviews·John Turnidge, David L Paterson

❮ Previous
Next ❯

Citations

Sep 16, 2010·The Journal of Antimicrobial Chemotherapy·Rodrigo E MendesRonald N Jones
Feb 4, 2012·Pediatric Dermatology·Scott BangertAdelaide A Hebert
Feb 24, 2011·Antimicrobial Agents and Chemotherapy·Emilio Pérez-TralleroVictor Iriarte
Apr 7, 2009·Expert Review of Anti-infective Therapy·Nicole E Scangarella-OmanDaryl Hoban
May 20, 2014·Clinical Therapeutics·Douglas J BiedenbachMeredith Hackel
Jun 26, 2013·Antimicrobial Agents and Chemotherapy·Louis D SaravolatzLeonard B Johnson
Jun 9, 2017·Clinical Microbiology Reviews·Deborah A WilliamsonBenjamin P Howden
Mar 24, 2017·The Journal of Antimicrobial Chemotherapy·Paulina A HawkinsLesley McGee
Mar 4, 2021·The Pediatric Infectious Disease Journal·Ami B PatelBo Shopsin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.